ASP 2409

Drug Profile

ASP 2409

Alternative Names: ASP2409

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Perseid Therapeutics
  • Developer Astellas Pharma
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 30 Apr 2014 Astellas Pharma completes a phase I trial in Rheumatoid arthritis in USA (NCT02171143)
  • 01 Nov 2013 Discontinued - Phase-I for Transplant rejection in Japan (Parenteral)
  • 01 Feb 2012 Phase-I clinical trials in Transplant rejection in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top